Login to Your Account



MHRA's Report On TeGenero Trial: Mostly, Nothing Wrong

By Nuala Moran


Wednesday, May 31, 2006
LONDON - The UK regulator uncovered some discrepancies with Good Clinical Practice in its investigation into the Phase I safety trial of TeGenero AG's TGN1412, but stuck to the original conclusion that the life-threatening cytokine storm suffered by six health volunteers was due to "an unexpected biological effect." (BioWorld International)

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription